Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below ...
Fennec Pharmaceuticals has FDA approval for Pedmark, a drug for cisplatin-triggered ototoxicity in children, with promising prospects. Financial concerns include decreasing cash, increasing ...
With one drug in its pipeline, 26-year-old Fennec Pharmaceuticals of North Carolina has had a lot riding on its treatment for chemotherapy-induced hearing loss. Finally, 18 years after it was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback